+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

HLA Typing Market by Product, Technology, Application, End User, and Geography - Forecast to 2029

  • PDF Icon

    Report

  • 233 Pages
  • October 2022
  • Region: Global
  • Meticulous Market Research Pvt. Ltd.
  • ID: 5661981
UP TO OFF until Jan 10th 2025
HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease], Research), End User, and Geography - Global Forecast to 2029

The Global HLA Typing Market is expected to grow at a CAGR of 5.6% from 2022 to 2029 to reach $1.90 billion by 2029.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the HLA typing market is attributed to the increasing number of organ transplants and technological advancements in the molecular assays used for HLA typing. In addition, the increasing awareness amongst people regarding organ donations offers a growth opportunity for the HLA typing market.

Based on product, in 2022, the consumables segment is estimated to account for the largest share of the HLA typing market. High demand for consumables, availability of diverse consumables, and companies focused on launching new HLA typing consumables contribute to the growth of this segment. For instance, in 2020, Omixon Inc. (U.S.) launched an 11-locus multiplex HLA genotyping assay.

Based on technology, in 2022, the molecular technologies segment is estimated to account for the largest share of the HLA typing market. Advancements and benefits of molecular technologies compared to non-molecular technologies contribute to the large share of this segment.

Based on application, in 2022, the diagnostics segment is expected to account for the largest share of the HLA typing market. The high prevalence of chronic and metabolic diseases leading to organ failures is responsible for the largest segment share. The application of HLA typing for donor-recipient cross-matching, infectious disease pathogenesis, and transfusion is rising, contributing to the largest segment share.

Based on end user, in 2022, the diagnostic laboratories segment is estimated to account for the largest share of the HLA typing market. HLA typing products are frequently used in diagnostics laboratories for disease diagnosis and donor-recipient cross-matching. Outsourcing laboratory services by hospitals and transplant centers and consolidating diagnostics laboratories contribute to the large share of this segment. The partnerships or outsourcing of laboratory services provides benefits such as cost savings, efficiency gains, and the right allocation of resources. Thus, the increasing collaboration between hospitals/transplant centers with diagnostic laboratories results in adoption of HLA typing products by diagnostic laboratories.

An in-depth analysis of the geographical scenario of the HLA typing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is estimated to account for the largest share of the HLA typing market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The highest number of organ transplants, high prevalence of chronic diseases, high spending on healthcare, and well-established healthcare infrastructure are the primary factors responsible for the large share of the North American HLA typing market.

Some of the key players operating in the global HLA typing market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Genome Diagnostics B.V. (GenDx) (Netherlands), Illumina, Inc. (U.S.), CareDx (U.S.), Immucor Inc. (U.S.), TBG Diagnostics Limited (Australia), BAG Diagnostic GmbH (Germany), Omixon Inc. (Hungary), Luminex Corporation (U.S.), inno-train Diagnostik GmbH (Germany), Pacific Biosciences of California, Inc. (U.S.), and Fujirebio Holdings, Inc. (Japan).

Scope of the Report:

HLA Typing Market, by Product

  • Consumables
  • Instruments
  • Software & Services

HLA Typing Market, by Technology

  • Molecular Technologies
  • PCR-based Molecular Techniques
  • Sequence-specific Primers
  • Sequence-specific Oligonucleotide
  • Other PCR-based Molecular Techniques
  • Other PCR-based molecular techniques include RPLF-PCR, SNP-PCR, and PCR-SSCP.
  • Sequencing-based Molecular Technologies
  • Sangers Sequencing
  • Next-generation Sequencing
  • Pyrosequencing
  • DNA Microarray
  • Non-molecular Technologies

HLA Typing Market, by Application

  • Diagnostics
  • Donor Recipient Cross-matching
  • Transfusion Therapy
  • Other Diagnostic Applications
  • Other diagnostic applications include Autoimmune Disease Diagnosis, Cancer Diagnosis, Infectious Disease Testing and Paternity testing.
  • Research

HLA Typing Market, by End Users

  • Diagnostics Laboratories
  • Hospitals & Transplant Centers
  • Academic & Research Institutes

HLA Typing Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLA)
  • Middle East & Africa

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Number of organ Transplants
4.2.2. Technological Advancements in HLA Typing
4.3. Restraints
4.3.1. High Cost of Instruments Required to HLA Typing
4.4. Opportunities
4.4.1. Increasing Awareness Regarding the Importance of Organ Donations
4.5. Challenges
4.5.1. Gap Between Organ Donations and Organ Receivers
4.6. Impact Analysis of COVID-19
5. Global HLA Typing Market, by Product
5.1. Introduction
5.2. Consumables
5.3. Instruments
5.4. Software & Services
6. Global HLA Typing Market, by Technology
6.1. Introduction
6.2. Molecular Technologies
6.2.1. PCR-based Molecular Techniques
6.2.1.1. Sequence-specific Primers
6.2.1.2. Sequence-specific Oligonucleotide
6.2.1.3. Other PCR-based Molecular Techniques
6.2.2. Sequencing-based Molecular Technologies
6.2.2.1. Sangers Sequencing
6.2.2.2. Next-generation Sequencing
6.2.2.3. Pyrosequencing
6.2.3. DNA Microarray
6.3. Non-molecular Technologies
7. Global HLA Typing Market, by Application
7.1. Introduction
7.2. Diagnostics
7.2.1. Donor Recipient Cross-Matching
7.2.2. Transfusion Therapy
7.2.3. Other Diagnostic Applications
7.3. Research
8. Global HLA Typing Market, by End User
8.1. Introduction
8.2. Diagnostics Laboratories
8.3. Hospitals & Transplant Centers
8.4. Academic & Research Institutes
9. HLA Typing Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America (RoLA)
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
11. Company Profiles (Business Overview, Financial Snapshot, Product Benchmarking, and Strategic Developments)
11.1. Becton, Dickinson and Company (BD)
11.2. Bio-Rad Laboratories, Inc.
11.3. Thermo Fisher Scientific Inc.
11.4. QIAGEN N.V.
11.5. Illumina Inc.
11.6. CareDx, Inc.
11.7. Genome Diagnostics B.V. (GenDx)
11.8. TBG Diagnostics Limited (TDL)
11.9. BAG Diagnostics GmbH
11.10. Omixon Inc.
11.11. Luminex Corporation
11.12. inno-train Diagnostik GmbH
11.13. Pacific Biosciences of California, Inc.
11.14. Fujirebio Holdings, Inc.
12. Appendix
12.1. Questionnaire
12.2. Available Customization

Companies Mentioned

  • Thermo Fisher Scientific Inc. (U.S.)
  • Bio-Rad Laboratories (U.S.)
  • Qiagen N.V. (Netherlands)
  • Genome Diagnostics B.V. (GenDx) (Netherlands)
  • Illumina Inc. (U.S.)
  • CareDx (U.S.)
  • Immucor Inc. (U.S.)
  • TBG Diagnostics Limited (Australia)
  • BAG Diagnostic GmbH (Germany)
  • Omixon Inc. (Hungary)
  • Luminex Corporation (U.S.)
  • inno-train Diagnostik GmbH (Germany)
  • Pacific Biosciences of California Inc. (U.S.)
  • Fujirebio Holdings Inc. (Japan)